Tomorrow, LXRX will be sharing Phase 2b topline results of their LX9211 non-opioid analgesic for DPNP.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
Trade closed: stop reached
okay, i learned that i cant do fundamental analysis. sticking to TA lmao 
just practicing & learning
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
just practicing & learning
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.